Abstract:In recent years, cancer immunotherapy has revolutionized cancer care. Remarkable clinical efficacy and durable responses to checkpoint blockade antibodies or to genetically engineered T-cells (CAR T cell) have been observed in patients with multiple cancers. However, not all cancer patients benefit from these therapies and as such novel immunotherapeutic approaches are needed. The cold atmospheric plasma (CAP) is a form of near room temperature ionized gas, which has shown a promising application in cancer therapy given its antitumor effects in vitro as well as in vivo. For the first time, we have shown that upon CAP treatment, the viability of the immune cells remained unaffected. Strikingly, we observed a significantly stronger immune activation of those CAP treated cells when compare with helium gas control. First, we have demonstrated that even without LPS stimulation, in vitro exposure of peritoneal elicited macrophages (PEM) to CAP for 15 or 30 seconds was sufficient to trigger the production of the pro-inflammatory cytokines IL-12 and IL-6. In addition, decreased production of anti-inflammatory cytokine IL-10 and diminished the expression of PD-L1 were observed in CAP-treated PEM as well. It indicated that CAP treatment may potentially facilitate PEMs as better activator of T cells. Second, in lieu of the stimulatory effects of CAP upon PEM, we asked whether CAP could enhance T-cell activation. So we isolated T cells from spleens of C57BL/6 mice and exposed these T cells to CAP followed by anti-CD3/CD28 stimulation. Our study shown that the production of IL-2 and IFN-g were significantly increased by T-cells treated with CAP as compared with helium gas control. Furthermore, to gain insights into effects of CAP upon immune responses in vivo, we isolated lymph nodes from OTII mice and directly exposed these LNs with CAP, helium gas control or left untreated. Then CD4+ T cells were further isolated from the LNs and cultured with macrophages in the presence or absence of OVA peptide for 48 hours, respectively. Surprisingly, CD4+ T cells isolated from CAP-treated LNs displayed enhanced function indicated by its increased production of IL-2 and IFN-g. More importantly, strong in vivo anti-tumor effects were observed when adoptively transfer CAP exposed T cells to lymphoma bearing animals. Taken together, we have shown for the first time an elevated immune-stimulatory effect of CAP upon both APCs and T cells in vitro and in vivo. Our finding may potentially shed light of a novel therapeutic approach for future cancer immunotherapy. Disclosures No relevant conflicts of interest to declare.

Pulsed voltage cold atmospheric plasma jet and goldnanoparticles enhance cytotoxic anticancer effect

Pulsed voltage cold atmospheric plasma jet and gold nanoparticles enhance cytotoxic anticancer effect

Advantages of Cold Atmospheric Plasma Jet Generated by Positive Pulse Voltage in Anti-Cancer Therapy

Cytotoxic Activity of a Cold Atmospheric Plasma Jet in Relation to a 3D Cell Model of Human Breast Cancer

Cold Atmospheric Plasma Activates Selective Photothermal Therapy of Cancer

Principles of using Cold Atmospheric Plasma Stimulated Media for Cancer Treatment

A New Physically Triggered Cell Death via Transbarrier Contactless Cold Atmospheric Plasma Treatment of Cancer Cells

Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines

Discharge Characteristics of a Microsecond Pulse Power Supply Driven Air Plasma Jet and Its Anticancer Cell Effect

Preclinical Cold Atmospheric Plasma Cancer Treatment

Enhancing Innate and Adaptive Immune Systems by Cold Atmospheric Plasma (CAP) and Its Antitumor Immunity

Unleashing the Power of Cold Atmospheric Plasma: Inducing Mitochondria Damage‐Mediated Mitotic Catastrophe

Cold-atmospheric plasma induces tumor cell death in preclinical in vivo and in vitro models of human cholangiocarcinoma

Cold atmospheric plasma sensitizes head and neck cancer to chemotherapy and immune checkpoint blockade therapy

Comprehensive studies on the biological activities of human metastatic (MDA-MB-231) and non-metastatic (MCF-7) breast cancer cell lines, directly or combinedly treated using non-thermal plasma-based approaches

NO2- and NO3- Enhance Cold Atmospheric Plasma Induced Cancer Cell Death by Generation of ONOO-

Platinum Nanoparticles to Enable Electrodynamic Therapy for Effective Cancer Treatment.

Cold Plasma with Immunomodulatory Properties Has Significant Anti-Lymphoma Activities in Vitro and In Vivo

Investigation of Optimum Discharge Characteristics and Chemical Activity of AC Driven Air Plasma Jet and Its Anticancer Effect

Micro-sized cold atmospheric plasma source for brain and breast cancer treatment

On the Mechanism of Plasma Inducing Cell Apoptosis